Volume 12, Number 5—May 2006
THEME ISSUE
Tuberculosis Special Section
Research
Mycobacterium tuberculosis and Rifampin Resistance, United Kingdom
Table 2
Sample and AFB smear result | No. positive/no. tested (%) |
|||||
---|---|---|---|---|---|---|
Concordance | Sensitivity | Specificity | PPV | NPV | Mean days saved | |
All primary LiPA | 775/782 (99.1) | 38/40 (95.0) | 737/740 (99.6) | 38/41 (92.7) | 738/740 (99.7) | 30.7 |
Positive | 743/747 (99.5) | 35/36 (97.2) | 708/710 (99.7) | 35/37 (94.6) | 709/710 (99.9) | 30.4 |
Negative | 32/35 (91.4) | 3/4 (75.0) | 29/30 (96.7) | 3/4 (75.0) | 29/30 (96.7) | 37.2 |
Not done | – | – | – | – | – | – |
Respiratory | 669/672 (99.6) | 32/33 (97.0) | 637/639 (99.7) | 32/34 (94.1) | 637/638 (99.8) | 30.4 |
Positive | 654/657 (99.5) | 31/32 (96.9) | 623/625 (99.7) | 31/33 (93.9) | 623/624 (99.8) | 30.2 |
Negative | 15/15 (100.0) | 1/1 (100.0) | 14/14 (100.0) | 1/1 (100.0) | 14/14 (100.0) | 39.1 |
Not done | – | – | – | – | – | – |
Nonrespiratory | 106/110 (96.4) | 6/7 (85.7) | 100/101 (99.0) | 6/7 (85.7) | 101/102 (99.0) | 32.5 |
Positive | 89/90 (98.9) | 4/4 (100.0) | 85/85 (100.0) | 4/4 (100.0) | 86/86 (100.0) | 32.0 |
Negative | 17/20 (85.0) | 2/3 (66.7) | 15/16 (93.8) | 2/3 (66.7) | 15/16 (93.8) | 35.5 |
Not done | – | – | – | – | – | – |
Clinical isolate | 229/235 (97.4) | 21/23 (91.3) | 208/211 (98.6) | 21/24 (87.5) | 208/210 (99.0) | 16.3 |
*LiPA, line probe assay; MTBC, Mycobacterium tuberculosis complex; AFB, acid-fast bacilli; PPV, positive predictive value; NPV, negative predictive value.
1Current affiliation: University of Malaya, Kuala Lumpur, Malaysia
Page created: January 06, 2012
Page updated: January 06, 2012
Page reviewed: January 06, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.